Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Urothelial Carcinoma”

67 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 67 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04152499
What this trial is testing

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

Who this might be right for
Epithelial Ovarian CancerGastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma+7 more
Klus Pharma Inc. 1,410
Testing effectiveness (Phase 2)Ended earlyNCT01732107
What this trial is testing

Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression

Who this might be right for
Bladder Cancer
Noah Hahn, M.D. 13
Testing effectiveness (Phase 2)UnknownNCT05318339
What this trial is testing

Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Carcinoma, Transitional CellHER-2 Gene Amplification
Chinese Academy of Medical Sciences 30
Early research (Phase 1)Study completedNCT03523572
What this trial is testing

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Who this might be right for
Breast CancerUrothelial Carcinoma
Daiichi Sankyo 86
Testing effectiveness (Phase 2)Looking for participantsNCT03945162
What this trial is testing

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Who this might be right for
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Theralase® Technologies Inc. 90
Early research (Phase 1)Study completedNCT00016237
What this trial is testing

Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment

Who this might be right for
Bladder CancerKidney CancerLung Cancer
EMD Serono
Large-scale testing (Phase 3)Study completedNCT00406068
What this trial is testing

Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder Neoplasms
Bioniche Life Sciences Inc. 129
Early research (Phase 1)Active Not RecruitingNCT04514484
What this trial is testing

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Who this might be right for
Advanced Differentiated Thyroid Gland CarcinomaAdvanced Head and Neck CarcinomaAdvanced Hepatocellular Carcinoma+60 more
National Cancer Institute (NCI) 8
Large-scale testing (Phase 3)Ended earlyNCT02982395
What this trial is testing

Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC

Who this might be right for
Non Muscle Invasive Bladder Cancer
Samyang Biopharmaceuticals Corporation 36
Early research (Phase 1)Study completedNCT01162785
What this trial is testing

1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer

Who this might be right for
Bladder Cancer
M.D. Anderson Cancer Center 7
Testing effectiveness (Phase 2)Active Not RecruitingNCT03333616
What this trial is testing

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Who this might be right for
Genitourinary CancerAdrenocortical CarcinomaNon-urothelial Bladder+5 more
Dana-Farber Cancer Institute 100
Testing effectiveness (Phase 2)Study completedNCT02844816
What this trial is testing

Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Who this might be right for
Recurrent Bladder Urothelial CarcinomaStage 0a Bladder Urothelial Carcinoma AJCC v6 and v7Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7+1 more
National Cancer Institute (NCI) 172
Testing effectiveness (Phase 2)Study completedNCT01780545
What this trial is testing

Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

Who this might be right for
Bladder CancerUrothelial Carcinoma
Noah Hahn, M.D. 200
Testing effectiveness (Phase 2)Ended earlyNCT01118351
What this trial is testing

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

Who this might be right for
Recurrent Bladder CancerTransitional Cell Carcinoma of the Bladder
Case Comprehensive Cancer Center 19
Testing effectiveness (Phase 2)Study completedNCT00003129
What this trial is testing

Chemotherapy in Treating Patients With Early-Stage Bladder Cancer

Who this might be right for
Bladder Cancer
Eastern Cooperative Oncology Group 75
Testing effectiveness (Phase 2)Active Not RecruitingNCT02202772
What this trial is testing

Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder

Who this might be right for
Urothelial Carcinoma of the Urinary Bladder
Guarionex J. Decastro 51
Testing effectiveness (Phase 2)Study completedNCT03636256
What this trial is testing

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

Who this might be right for
Bladder CancerUrothelial CarcinomaUrinary Bladder Neoplasm+6 more
NanOlogy, LLC 36
Testing effectiveness (Phase 2)Ended earlyNCT02901548
What this trial is testing

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Who this might be right for
Carcinoma in Situ of BladderBladder Cancer
H. Lee Moffitt Cancer Center and Research Institute 17
Early research (Phase 1)Study completedNCT03739931
What this trial is testing

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Who this might be right for
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or LymphomaDose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
ModernaTX, Inc. 134
Testing effectiveness (Phase 2)Active Not RecruitingNCT04164082
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder Flat Urothelial Carcinoma In SituNon-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8+2 more
National Cancer Institute (NCI) 161
Load More Results